DEXEDRINE Drug Patent Profile

« Back to Dashboard

When do Dexedrine patents expire, and what generic alternatives are available?

Dexedrine is a drug marketed by Glaxosmithkline and Impax Labs Inc and is included in three NDAs.

The generic ingredient in DEXEDRINE is dextroamphetamine sulfate. There is one drug master file entry for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the dextroamphetamine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dexedrine

A generic version of DEXEDRINE was approved as dextroamphetamine sulfate by BARR on January 31^st, 2001.

Summary for DEXEDRINE

US Patents:	0
Applicants:	2
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	16
Drug Prices:	Drug price information for DEXEDRINE
What excipients (inactive ingredients) are in DEXEDRINE?	DEXEDRINE excipients list
DailyMed Link:	DEXEDRINE at DailyMed

See drug prices for DEXEDRINE

Recent Clinical Trials for DEXEDRINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shire	Phase 4
JPM van Stralen Medicine Professional	Phase 4
Brain & Behavior Research Foundation	Phase 1/Phase 2

See all DEXEDRINE clinical trials

US Patents and Regulatory Information for DEXEDRINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	DEXEDRINE	dextroamphetamine sulfate	ELIXIR;ORAL	083902-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Impax Labs Inc	DEXEDRINE SPANSULE	dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	017078-002	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Glaxosmithkline	DEXEDRINE	dextroamphetamine sulfate	TABLET;ORAL	084935-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Impax Labs Inc	DEXEDRINE SPANSULE	dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	017078-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Impax Labs Inc	DEXEDRINE SPANSULE	dextroamphetamine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	017078-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

DEXEDRINE Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: October 5, 2026

DEXEDRINE is the legacy U.S. brand for dextroamphetamine sulfate, an immediate-release and extended-release stimulant used primarily for attention-deficit/hyperactivity disorder and narcolepsy. Its commercial position is mature and largely genericized. The principal value drivers are product availability, controlled-substance quotas, pharmacy access, manufacturing capacity, and competition from amphetamine mixed salts, lisdexamfetamine, methylphenidate, and newer nonstimulants.

No public company reports standalone DEXEDRINE revenue. The product’s financial trajectory is therefore best assessed through prescription demand, generic competition, FDA supply data, regulatory status, and the economics of a low-price controlled-substance market.

What is DEXEDRINE and how is it used?

DEXEDRINE contains dextroamphetamine sulfate, the dextrorotatory amphetamine isomer. The product has been marketed in two principal dosage forms:

Product	Active ingredient	Typical role
DEXEDRINE tablets	Dextroamphetamine sulfate immediate release	Shorter-duration stimulant treatment
DEXEDRINE SPANSULE capsules	Dextroamphetamine sulfate extended release	Longer-duration treatment

The U.S. labeling identifies DEXEDRINE tablets and SPANSULE capsules for narcolepsy and attention-deficit disorder with hyperactivity. The labeling also carries boxed-warning language concerning abuse, misuse, addiction, and serious cardiovascular and psychiatric risks associated with stimulant use (FDA, 2023a).

Dextroamphetamine is a Schedule II controlled substance under the federal Controlled Substances Act. That classification affects prescribing, refills, inventory controls, quota allocation, theft prevention, and manufacturing economics.

What is the FDA regulatory status of DEXEDRINE?

DEXEDRINE is an FDA-approved prescription stimulant, but its commercial status differs from that of a newly marketed branded drug.

The FDA-approved product history includes:

• Immediate-release dextroamphetamine sulfate tablets.
• Extended-release DEXEDRINE SPANSULE capsules.
• Generic immediate-release dextroamphetamine sulfate tablets.
• Generic extended-release dextroamphetamine sulfate capsules.

FDA labeling and product databases distinguish between the legacy brand product and generic abbreviated new drug application products. The presence of an FDA-approved generic does not mean that the original brand has a meaningful branded market share.

The FDA’s Orange Book is the principal source for identifying approved products, therapeutic equivalence, patents, and regulatory exclusivity. DEXEDRINE’s core composition and dosage-form rights date from an era in which the relevant product and formulation patents have expired. The current commercial barrier is therefore operational rather than patent-based (FDA, 2024a).

What patents protect DEXEDRINE?

No current Orange Book patent estate appears to provide meaningful exclusivity for the core DEXEDRINE tablets or SPANSULE products.

Patent and exclusivity profile

Protection category	Current commercial significance
Core dextroamphetamine sulfate composition	Expired
Immediate-release tablet formulation	Expired or no longer commercially exclusionary
Legacy extended-release SPANSULE technology	Expired legacy protection
Orange Book listed patents	No material current barrier identified for routine generic entry
FDA new-drug exclusivity	Expired
Pediatric exclusivity	No current commercial effect
Method-of-use patents	No known active estate that blocks ordinary generic dextroamphetamine use
Manufacturing patents	Potentially relevant to individual suppliers, but not a product-level barrier

The absence of meaningful active patent protection means that a generic applicant would not normally need to overcome a substantial patent wall before marketing dextroamphetamine sulfate. A Paragraph IV challenge is therefore not the central market event for DEXEDRINE. The relevant generic pathways are standard ANDA approvals, manufacturing supplements, product transfers, and supplier re-entry after shortages.

How many patents cover DEXEDRINE?

The practical answer is zero material blocking patents for the legacy commercial product based on the FDA Orange Book framework. Historical patents may appear in archival records, patent databases, or litigation filings, but expired patents do not support current market exclusivity.

Patent risk can still arise around:

• New abuse-deterrent delivery systems.
• Combination products.
• Alternative release profiles.
• Digital adherence systems.
• New salts, prodrugs, or chemical entities.
• Manufacturing processes not listed as product patents.

Those potential innovations would be separate from the legacy DEXEDRINE estate.

When did DEXEDRINE lose exclusivity?

DEXEDRINE lost meaningful exclusivity decades ago. The product’s active pharmaceutical ingredient and conventional dosage forms are established generic products, and the FDA has approved multiple dextroamphetamine sulfate products.

The commercial timeline is:

Period	Market event
Historical period	Original DEXEDRINE products marketed for narcolepsy and hyperactivity disorders
Genericization period	ANDA-approved dextroamphetamine sulfate products entered the U.S. market
Mature market period	Brand and generic products competed primarily on availability and price
Current market	Generic supply, controlled-substance quotas, and shortage conditions determine access

The exact historical date of first generic entry is less important commercially than the current fact that no effective brand exclusivity remains. FDA approval records and the Orange Book provide the operative regulatory evidence (FDA, 2024a; FDA, 2024b).

What is the Orange Book status of DEXEDRINE?

The Orange Book treats DEXEDRINE as a legacy prescription drug with generic equivalents in the relevant dosage forms. The key commercial implications are:

1. Generic substitution is legally available where state pharmacy law and prescriber instructions permit it.
2. The branded product cannot rely on patent-based blocking rights.
3. Generic manufacturers compete through ANDA approval, supply reliability, wholesaler access, and pricing.
4. Any remaining branded demand is likely concentrated among patients and prescribers with product-specific preferences.

Therapeutic equivalence ratings apply at the product level and dosage form level. An FDA-rated generic may be substitutable for the corresponding reference product, subject to state law and prescription instructions. Extended-release and immediate-release products are not interchangeable merely because both contain dextroamphetamine.

What drives DEXEDRINE market demand?

Demand is tied mainly to ADHD diagnosis and treatment, narcolepsy prevalence, stimulant prescribing patterns, and patient response to different amphetamine formulations.

ADHD demand

ADHD is the larger demand pool. The CDC reports that millions of U.S. children and adolescents have received an ADHD diagnosis, with a substantial number receiving medication treatment. Adult ADHD treatment has also expanded, increasing demand for stimulant products across different age groups (CDC, 2024).

DEXEDRINE competes with:

• Adderall immediate-release tablets.
• Adderall XR and generic mixed amphetamine salts extended-release products.
• Vyvanse and generic lisdexamfetamine.
• Ritalin and generic methylphenidate.
• Concerta and other extended-release methylphenidate products.
• Atomoxetine.
• Guanfacine extended release.
• Clonidine extended release.

Dextroamphetamine’s clinical positioning is strongest where prescribers want a pure dextroamphetamine product, a short-acting formulation, or an alternative after inadequate response or adverse effects with methylphenidate or mixed amphetamine salts.

Narcolepsy demand

Narcolepsy is a smaller market than ADHD but provides an established indication. Treatment competition includes modafinil, armodafinil, solriamfetol, pitolisant, sodium oxybate products, and other stimulants. DEXEDRINE’s price and familiarity can support continued use, but newer agents compete on wakefulness efficacy, abuse potential, duration, and tolerability.

How does DEXEDRINE compare with Adderall and Vyvanse?

Attribute	DEXEDRINE	Adderall	Vyvanse
Active ingredient	Dextroamphetamine sulfate	Mixed amphetamine salts	Lisdexamfetamine
Pharmacology	Dextroamphetamine	Dextroamphetamine and levoamphetamine salts	Prodrug converted to dextroamphetamine
Immediate-release form	Yes	Yes	No conventional immediate-release form
Extended-release form	SPANSULE legacy product	XR	Long-acting capsule and chewable forms
Generic competition	Established	Established	Generic available after loss of exclusivity
Main commercial differentiator	Pure dextroamphetamine and availability	Broad prescribing familiarity	Long duration and prodrug profile
Supply risk	Manufacturer and quota dependent	Historically significant shortage exposure	Supply and conversion-capacity dependent
Patent strength	Minimal for legacy product	Legacy estate largely expired	Older product protection expired; newer product-specific issues may differ

Adderall has greater commercial scale and broader awareness. Vyvanse has historically commanded a higher price because of its branded long-acting profile and prodrug design, although generic lisdexamfetamine has changed that pricing structure. DEXEDRINE occupies a narrower, older segment with limited pricing power.

What generic entry risks exist for DEXEDRINE?

The main risk is not future generic entry. Generic products are already present. The commercial risk is generic supply concentration and intermittent shortages.

Generic manufacturers face several barriers:

• Schedule II quota limits.
• Active pharmaceutical ingredient availability.
• FDA manufacturing compliance.
• Controlled-substance security requirements.
• Low margin per prescription.
• Inventory restrictions at wholesalers and pharmacies.
• Complex demand forecasting after shortages in competing stimulants.
• State-specific substitution and prescribing rules.

These conditions can create a market in which a product is legally genericized but practically unavailable. A manufacturer with reliable supply can gain share without owning patent rights.

What shortage and supply issues affect DEXEDRINE?

The FDA has documented shortages involving dextroamphetamine products and other prescription stimulants. Shortages have reflected a combination of manufacturing delays, increased demand, active pharmaceutical ingredient constraints, and controlled-substance production limits (FDA, 2024c).

Shortage dynamics affect DEXEDRINE in four ways:

1. Patients may switch between manufacturers or dosage forms.
2. Prescribers may move patients to Adderall, Vyvanse, methylphenidate, or nonstimulants.
3. Pharmacies may limit new stimulant prescriptions because of inventory uncertainty.
4. Manufacturers with available quota and dependable distribution can capture temporary volume.

Shortages can increase prescription switching while reducing realized sales if the manufacturer cannot fill orders. They also raise the value of supply continuity relative to brand recognition.

What is the financial trajectory for DEXEDRINE?

DEXEDRINE has the financial profile of a mature genericized controlled substance:

• Low or limited branded pricing power.
• No meaningful patent-protected price period.
• Volume dependent on ADHD and narcolepsy treatment demand.
• Revenue exposed to generic substitution.
• Margin sensitivity to manufacturing scale and shortage conditions.
• Potential temporary price increases when supply contracts.
• No reliable public standalone revenue series.

The product’s financial trajectory is therefore likely flat to declining in normalized branded terms, with episodic volume and pricing volatility caused by shortages. Any individual manufacturer can experience revenue growth through supply capture, but that does not establish durable market expansion for the DEXEDRINE brand.

Public disclosures from diversified pharmaceutical companies generally aggregate dextroamphetamine products within broader generic or prescription-drug revenue categories. They do not isolate DEXEDRINE revenue sufficiently to calculate brand-level annual sales, EBITDA, or market share. IQVIA, Symphony Health, and other commercial datasets may contain prescription and sales estimates, but those data are not generally disclosed in public company filings.

Revenue exposure scenarios

Scenario	Market effect	Financial implication
Stable generic supply	Price competition persists	Low-to-moderate predictable revenue
Competitor shortage	Temporary share gains	Higher volume and possible price improvement
DEXEDRINE supply disruption	Prescriptions shift to alternatives	Revenue loss and replenishment risk
New long-acting competitor	Prescriber migration	Structural volume pressure
Increased ADHD treatment demand	Larger stimulant pool	Positive volume effect, limited pricing power
Regulatory tightening	Lower access or higher compliance cost	Margin and volume pressure

Which companies are challenging or competing with DEXEDRINE?

The competitive set includes generic manufacturers of dextroamphetamine sulfate and companies selling alternative stimulant products. Relevant competitors include manufacturers of:

• Generic dextroamphetamine sulfate tablets and extended-release capsules.
• Generic mixed amphetamine salts.
• Generic lisdexamfetamine.
• Generic methylphenidate.
• Branded and generic narcolepsy therapies.

The competitive market is fragmented. Manufacturer identity may change through product transfers, acquisitions, discontinuations, and temporary supply decisions. FDA’s Drugs@FDA, Orange Book, and Drug Shortages databases are more reliable for current product status than historical brand marketing materials (FDA, 2024a; FDA, 2024b; FDA, 2024c).

What litigation and settlement agreements affect DEXEDRINE?

No major current patent litigation or settlement appears to define the DEXEDRINE market. The product’s core patents are expired, and generic entry is established.

The principal legal risks are instead:

• Controlled-substance distribution enforcement.
• Failure to comply with FDA current good manufacturing practice requirements.
• Product liability claims.
• False advertising or improper promotion.
• Diversion and suspicious-order monitoring.
• State pharmacy and prescribing enforcement.
• Antitrust scrutiny involving generic supply or distribution practices.

Paragraph IV litigation is not a central current risk for the legacy product because the relevant patent barrier has already eroded. Any future litigation would more likely concern a newly developed formulation, abuse-deterrent technology, or a separate dextroamphetamine product.

How strong is the DEXEDRINE patent estate?

The legacy DEXEDRINE patent estate is weak from a commercial exclusivity perspective. Its strengths are historical brand recognition, regulatory familiarity, established clinical use, and a known active ingredient. Its weaknesses are generic substitution, no effective patent wall, limited pricing power, and competition from multiple amphetamine and non-amphetamine products.

The strongest defensible position would not come from the original DEXEDRINE product. It would come from a differentiated formulation with a new patent estate, such as a long-acting delivery system, abuse-deterrent design, improved tolerability profile, or clinically differentiated combination.

Key Takeaways

• DEXEDRINE is a mature dextroamphetamine sulfate product with no meaningful current patent exclusivity.
• Generic competition is established in immediate-release and extended-release dosage forms.
• The principal market constraint is supply reliability, not intellectual property.
• ADHD is the main demand driver; narcolepsy is a smaller but established indication.
• Adderall, Vyvanse, methylphenidate products, and nonstimulants are the principal competitors.
• Public filings do not provide standalone DEXEDRINE revenue or profit data.
• Normalized financial performance is likely low-growth, with temporary upside during competitor shortages.
• Generic manufacturers with reliable quota, API access, and distribution can capture share without patent protection.
• No major current Paragraph IV challenge, patent settlement, or blocking litigation defines the product market.
• Any new commercial opportunity would require differentiated formulation or delivery technology rather than the legacy DEXEDRINE brand.

FAQs

Is DEXEDRINE still available in the United States?

FDA-approved dextroamphetamine sulfate products remain part of the U.S. prescription market, but availability can vary by dosage form, manufacturer, pharmacy inventory, and shortage conditions.

Is DEXEDRINE generic?

Dextroamphetamine sulfate is available as a generic product. DEXEDRINE is the legacy brand name associated with dextroamphetamine sulfate tablets and SPANSULE extended-release capsules.

Does DEXEDRINE have patent protection?

The legacy DEXEDRINE products do not have a commercially meaningful active patent estate that prevents ordinary generic competition.

Is DEXEDRINE stronger than Adderall?

The products cannot be compared solely by milligram strength because DEXEDRINE contains dextroamphetamine, while Adderall contains mixed amphetamine salts. Clinical effect depends on dose, formulation, patient response, and prescriber management.

Can a new company obtain exclusivity for a dextroamphetamine product?

Yes, but exclusivity would need to arise from a new product or formulation, such as a novel delivery system, abuse-deterrent technology, or other patentable innovation. The existing DEXEDRINE formulation does not provide a practical route to market exclusivity.

References

Centers for Disease Control and Prevention. (2024). Data and statistics on ADHD. https://www.cdc.gov/adhd/data/index.html

U.S. Food and Drug Administration. (2023a). DEXEDRINE tablets and DEXEDRINE SPANSULE capsules prescribing information. FDA.

U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

U.S. Food and Drug Administration. (2024c). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/